CytomX Therapeutics (CTMX) Receivables - Other (2016 - 2025)
CytomX Therapeutics (CTMX) has disclosed Receivables - Other for 11 consecutive years, with $400000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Other fell 63.64% year-over-year to $400000.0, compared with a TTM value of $400000.0 through Sep 2025, down 63.64%, and an annual FY2024 reading of $1.1 million, changed N/A over the prior year.
- Receivables - Other was $400000.0 for Q3 2025 at CytomX Therapeutics, down from $900000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $12.1 million in Q1 2024 and bottomed at $400000.0 in Q3 2025.
- Average Receivables - Other over 5 years is $1.7 million, with a median of $1.0 million recorded in 2022.
- The sharpest move saw Receivables - Other crashed 99.0% in 2021, then skyrocketed 1110.0% in 2024.
- Year by year, Receivables - Other stood at $800000.0 in 2021, then surged by 112.5% to $1.7 million in 2022, then dropped by 23.53% to $1.3 million in 2023, then dropped by 15.38% to $1.1 million in 2024, then crashed by 63.64% to $400000.0 in 2025.
- Business Quant data shows Receivables - Other for CTMX at $400000.0 in Q3 2025, $900000.0 in Q2 2025, and $900000.0 in Q1 2025.